Table 1.
Distribution of clinical, laboratory, and radiological variables in patients with fibrin-predominant clot (FPC) vs. the rest.
| FPC, n = 100 (%) | Rest, n = 89 (%) | p | |
|---|---|---|---|
| Age, mean (SD) | 69.5 (13) | 69.6 (11.4) | 0.97 |
| Sex, male | 50 (50) | 50 (56.2) | 0.47 |
| Arterial hypertension | 75 (75) | 61 (68.5) | 0.34 |
| Diabetes mellitus | 30 (30) | 23 (25.8) | 0.63 |
| Dyslipidemia | 41 (41) | 37 (41.6) | 1 |
| Ischemic heart disease | 11 (11) | 10 (11.2) | 1 |
| Smoking | 11 (11) | 16 (18) | 0.17 |
| Oral anticoagulation | 32 (32) | 17 (19.1) | 0.042 |
| Atherothrombotic | 14 (14) | 13 (14.6) | 1 |
| Cardioembolic | 63 (63) | 48 (53.9) | 0.24 |
| Baseline NIHSS, median (IQ) | 17 (13–23) | 18 (10–24) | 0.7 |
| Glucose mg/dL, mean (SD) | 138.4 | 138.9 | 0.95 |
| WBC/mm3, mean (SD) | 9.228 (2,961) | 9.777 (3,158) | 0.22 |
| Neutrophils /mm3, mean (SD) | 6,454 (2,908) | 7,285 (3,436) | 0.073 |
| Lymphocytes /mm3, mean (SD) | 1,747 (1,007) | 1,784 (895) | 0.79 |
| Ratio Neutrophils / Lymphocytes, mean (SD) | 5.6 (5.6) | 5.5 (4.4) | 0.94 |
| Monocytes /mm3, mean (SD) | 479 (194) | 463 (216) | 0.61 |
| Platelets /mm3, mean (SD) | 223,010 (67,274) | 219,750 (93,025) | 0.78 |
| Fibrinogen mg/dL, mean (SD) | 322.9 | 338.8 | 0.58 |
| CRP * mg/dL, mean (SD) | 51.5 (61.7) | 32.3 (32.3) | 0.02 |
| Tandem occlusion | 16 (16) | 19 (21.3) | 0.35 |
| Distal occlusion (M2+M3) | 24 (24) | 14 (15.7) | 0.15 |
| ASPECTS, median (IQ) | 9 (8–10) | 9 (8–10) | 0.7 |
| HMCA | 55 (55) | 61 (68.5) | 0.039 |
| HU pathological side, mean (SD) | 52.8 (9.4)7 | 54.4 (9.3) | 0.35 |
| HU ratio, mean (SD) | 1.44 (0.3)7 | 1.43 (0.4) | 0.94 |
| Mismatch, **mean (SD) | 80.8 (20)7 | 81.6 (18.7) | 0.8 |
| Alteplase IV | 32 (32) | 41 (46.1) | 0.047 |
| PH-2 | 3 (3) | 1 (1.1) | 0.36 |
| Onset-CT, mean min (SD) | 375 (470.1) | 377.4 (480.4) | 0.97 |
| Onset-groin, mean min (SD) | 496.1 (602.1) | 407.1 (470.7) | 0.26 |
| Procedure time, mean min (SD) | 36.1 (25.2) | 37.8 (25.3) | 0.63 |
| Number of passes, mean (SD) | 1.8 (1.2) | 1.7 (1.2) | 0.6 |
| Single-pass recanalization | 43 (43) | 32 (36) | 0.32 |
| TICI 2B | 13 (61.9) | 87 (51.8) | 0.49 |
| Stent retriever | 85 (85) | 72 (80.9) | 0.71 |
| Aspiration | 13 (13) | 14 (15.7) | 0.6 |
| mRS ≤ 2 at 3 months | 68 (68) | 60 (60) | 0.93 |
| Mortality | 11 (11) | 2 (2.2) | 0.012 |
Calculated over a total of 147 (77.8%) patients with CRP measured after the endovascular procedure.
Calculated over a total of 140 (74.1%) patients with a measurable perfusion study.
ASPECTS, Alberta Stroke Protocol Early CT Score; CRP, C-reactive protein; CT, computed tomography; DLP, dyslipidemia; DM, diabetes mellitus; FPC, fibrin-predominant clot; HBP, high blood pressure; HMCA, hyperdensity of the middle cerebral artery; HU, Hounsfield units; IQ, interquartile range; IV, intravenous; M2, 2nd segment of the middle cerebral artery; M3, 3rd segment of the middle cerebral artery; mRS, modified Rankin score; NIHSS, National Institute of Health Stroke Scale; OAC, oral anticoagulation; PH-2, type 2 parenchymal hemorrhagic transformation; SD, standard deviation; TICI, thrombolysis in cerebral infarction; WBC, white blood cell. The bold values indicated to highlight the results.